Citigroup

Filing Details

13F-HR • 2025-03-31
Report Date
2025-03-31
Filing Date
2025-05-12
Total Holdings
8,340
Total Value
44847690535
Accession Number
0000831001-25-000103
Form Type
13F-HR
Manager Name
Citigroup
Data Enrichment
86% identified
7,168 identified1,172 unidentified

Holdings

8,340 positions • $44.8B total value
Manager:
Search and click to pin securities to the top
Page 224 of 239
ACHIEVE LIFE SCIENCES, INC.
Shares:342
Value:$913
% of Portfolio:0.0% ($913/$44.8B)
VERU INC.
Shares:1.9K
Value:$908
% of Portfolio:0.0% ($908/$44.8B)
450047303
Shares:70
Value:$903
% of Portfolio:0.0% ($903/$44.8B)
AUDIOEYE INC
Shares:81
Value:$899
% of Portfolio:0.0% ($899/$44.8B)
Larimar Therapeutics, Inc.
Shares:418
Value:$898
% of Portfolio:0.0% ($898/$44.8B)
Adverum Biotechnologies, Inc.
Shares:205
Value:$896
% of Portfolio:0.0% ($896/$44.8B)
Kronos Bio, Inc.
Shares:1.1K
Value:$889
% of Portfolio:0.0% ($889/$44.8B)
Cabaletta Bio, Inc.
Shares:633
Value:$876
% of Portfolio:0.0% ($876/$44.8B)
TAYLOR DEVICES, INC.
Shares:27
Value:$871
% of Portfolio:0.0% ($871/$44.8B)
Waldencast plc
Shares:289
Value:$867
% of Portfolio:0.0% ($867/$44.8B)
Upstream Bio, Inc.
Shares:141
Value:$863
% of Portfolio:0.0% ($863/$44.8B)
Septerna, Inc.
Shares:149
Value:$863
% of Portfolio:0.0% ($863/$44.8B)
EGAIN Corp
Shares:176
Value:$854
% of Portfolio:0.0% ($854/$44.8B)
Nanobiotix S.A.
Shares:241
Value:$853
% of Portfolio:0.0% ($853/$44.8B)
Cardlytics, Inc.
Shares:468
Value:$852
% of Portfolio:0.0% ($852/$44.8B)
Neumora Therapeutics, Inc.
Shares:850
Value:$850
% of Portfolio:0.0% ($850/$44.8B)
ATOSSA THERAPEUTICS, INC.
Shares:1.3K
Value:$850
% of Portfolio:0.0% ($850/$44.8B)
MARKETWISE, INC.
Shares:1.7K
Value:$849
% of Portfolio:0.0% ($849/$44.8B)
Lineage Cell Therapeutics, Inc.
Shares:1.9K
Value:$844
% of Portfolio:0.0% ($844/$44.8B)
NL INDUSTRIES INC
Shares:105
Value:$830
% of Portfolio:0.0% ($830/$44.8B)